Skip to main content
SpringerLink
Log in

Adverse Effects of Immunosuppression: Infections

  • Chapter
  • First Online:
Pharmacology of Immunosuppression

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 272))

Abstract

Immunosuppressive therapies are currently indicated for a wide range of diseases. As new agents emerge and indications evolve the landscape grows increasingly complex. Therapies can target pathologic immune system over-activation in rheumatologic or autoimmune disease, or conditioning and graft versus host disease (GVHD) prophylactic regimens may eliminate or inhibit host immune function to improve graft survival and risk of complication in solid organ transplantation (SOT) or hematopoietic stem cell transplantation (HSCT). With immunosuppressive therapy, infections occur. Complex disease states, host factors, and concomitant therapies contribute to a “net state” of immunosuppression that must be considered and may confound perceived increased infection risks in patients receiving treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Achtnichts L, Obreja O, Conen A, Fux CA, Nedeltchev K (2015) Cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimod. JAMA Neurol 72(10):1203–1205

    Article  PubMed  Google Scholar 

  • Adams AB, Goldstein J, Garrett C et al (2017) Belatacept combined with transient calcineurin inhibitor therapy prevents rejection and promotes improved long-term renal allograft function. Am J Transplant 17(11):2922–2936

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Allison AC, Eugui EM (2005) Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 80(2 Suppl):S181–S190

    Article  CAS  PubMed  Google Scholar 

  • Ansari D, Lund LH, Stehlik J et al (2015) Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab. J Heart Lung Transplant 34(10):1283–1291

    Article  PubMed  Google Scholar 

  • Arai Y, Jo T, Matsui H, Kondo T, Takaori-Kondo A (2017) Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Leuk Lymphoma 58(8):1840–1848

    Article  CAS  PubMed  Google Scholar 

  • Ariza-Heredia EJ, Nesher L, Chemaly RF (2014) Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett 342(1):1–8

    Article  CAS  PubMed  Google Scholar 

  • Arvin AM, Wolinsky JS, Kappos L et al (2015) Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol 72(1):31–39

    Article  PubMed  PubMed Central  Google Scholar 

  • Barmettler S, Ong MS, Farmer JR, Choi H, Walter J (2018) Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 1(7):e184169

    Article  PubMed  PubMed Central  Google Scholar 

  • Basic-Jukic N, Kes P, Bubic-Filipi LJ et al (2005) Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation? Transplant Proc 37(2):850–851

    Article  CAS  PubMed  Google Scholar 

  • Berger JR (2017) Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 12:59–63

    Article  PubMed  Google Scholar 

  • Bergstrom L, Yocum DE, Ampel NM et al (2004) Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 50(6):1959–1966

    Article  CAS  PubMed  Google Scholar 

  • Berzero G, Basso S, Stoppini L et al (2021) Adoptive transfer of JC virus-specific T lymphocytes for the treatment of progressive multifocal leukoencephalopathy. Ann Neurol 89(4):769–779

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Biehl A, Harinstein L, Brinker A, Glaser R, Munoz M, Avigan M (2021) A case series analysis of serious exacerbations of viral hepatitis and non-viral hepatic injuries in tocilizumab-treated patients. Liver Int 41(3):515–528

    Article  CAS  PubMed  Google Scholar 

  • Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D, Thymoglobulin Induction Study Group (2006) Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 355(19):1967–1977

    Article  CAS  PubMed  Google Scholar 

  • Breuer GS, Ehrenfeld M, Rosner I et al (2014) Late-onset neutropenia following rituximab treatment for rheumatologic conditions. Clin Rheumatol 33(9):1337–1340

    Article  PubMed  Google Scholar 

  • Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A (2010) Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 6(12):667–679

    Article  PubMed  Google Scholar 

  • Burmester GR, Rubbert-Roth A, Cantagrel A et al (2014) A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 73(1):69–74

    Article  CAS  PubMed  Google Scholar 

  • Buti M, Manzano ML, Morillas RM et al (2017) Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: the Preblin study. PLoS One 12(9):e0184550

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Calabresi PA, Radue EW, Goodin D et al (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 13(6):545–556

    Article  CAS  PubMed  Google Scholar 

  • Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ (2011) Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 50(3):552–562

    Article  CAS  Google Scholar 

  • Caocci G, Murgia F, Podda L, Solinas A, Atzeni S, La Nasa G (2014) Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 28(1):225–227

    Article  CAS  PubMed  Google Scholar 

  • Carson KR, Newsome SD, Kim EJ et al (2014) Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 120(16):2464–2471

    Article  CAS  PubMed  Google Scholar 

  • Casulo C, Maragulia J, Zelenetz AD (2013) Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 13(2):106–111

    Article  CAS  PubMed  Google Scholar 

  • Charpentier B, Rostaing L, Berthoux F et al (2003) A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 75(6):844–851

    Article  CAS  PubMed  Google Scholar 

  • Chen YM, Huang WN, Wu YD et al (2018) Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis 77(5):780–782

    Article  CAS  PubMed  Google Scholar 

  • Choi J, Aubert O, Vo A et al (2017) Assessment of tocilizumab (anti-Interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant 17(9):2381–2389

    Article  CAS  PubMed  Google Scholar 

  • Chun J, Hartung HP (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33(2):91–101

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cohen SB, Moreland LW, Cush JJ et al (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63(9):1062–1068

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362(5):402–415

    Article  CAS  PubMed  Google Scholar 

  • Cohen SB, Tanaka Y, Mariette X et al (2017) Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 76(7):1253–1262

    Article  CAS  PubMed  Google Scholar 

  • Coiffier B, Lepretre S, Pedersen LM et al (2008) Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 111(3):1094–1100

    Article  CAS  PubMed  Google Scholar 

  • Colomba C, Rubino R, Siracusa L et al (2012) Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes 5:552

    Article  PubMed  PubMed Central  Google Scholar 

  • Colombel JF, Sands BE, Rutgeerts P et al (2017) The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 66(5):839–851

    Article  CAS  PubMed  Google Scholar 

  • Comi G, Kappos L, Selmaj KW et al (2019) Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol 18(11):1009–1020

    Article  CAS  PubMed  Google Scholar 

  • Confavreux C, O'Connor P, Comi G et al (2014) Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13(3):247–256

    Article  CAS  PubMed  Google Scholar 

  • Couriel D, Saliba R, Hicks K et al (2004) Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 104(3):649–654

    Article  CAS  PubMed  Google Scholar 

  • Creed TJ, Norman MR, Probert CS et al (2003) Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 18(1):65–75

    Article  CAS  PubMed  Google Scholar 

  • Cronstein BN (1996) Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 39(12):1951–1960

    Article  CAS  PubMed  Google Scholar 

  • Danese S, Vermeire S, Hellstern P et al (2019) Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II). Gut 68(1):40–48

    Article  CAS  PubMed  Google Scholar 

  • De Benedetti F, Gattorno M, Anton J et al (2018) Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med 378(20):1908–1919

    Article  PubMed  Google Scholar 

  • den Broeder AA, Creemers MC, Fransen J et al (2007) Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 34(4):689–695

    Google Scholar 

  • Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH (2015) Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 61(2):703–711

    Article  PubMed  CAS  Google Scholar 

  • Dixon WG, Hyrich KL, Watson KD et al (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69(3):522–528

    Article  CAS  PubMed  Google Scholar 

  • Dougados M, van der Heijde D, Chen YC et al (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76(1):88–95

    Article  CAS  PubMed  Google Scholar 

  • Drobyski WR, Pasquini M, Kovatovic K et al (2011) Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant 17(12):1862–1868

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Durrbach A, Pestana JM, Florman S et al (2016) Long-term outcomes in belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study. Am J Transplant 16(11):3192–3201

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Emery P, Keystone E, Tony HP et al (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67(11):1516–1523

    Article  CAS  PubMed  Google Scholar 

  • Emre S, Gondolesi G, Polat K et al (2001) Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 7(3):220–225

    Article  CAS  PubMed  Google Scholar 

  • Epstein DJ, Dunn J, Deresinski S (2018) Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis 5(8):ofy174

    Article  PubMed  PubMed Central  Google Scholar 

  • Feagan BG, Rutgeerts P, Sands BE et al (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369(8):699–710

    Article  CAS  PubMed  Google Scholar 

  • Fine AJ, Sorbello A, Kortepeter C, Scarazzini L (2013) Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin Infect Dis 57(6):849–852

    Article  CAS  PubMed  Google Scholar 

  • Fleischmann RM, Schechtman J, Bennett R et al (2003) Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 48(4):927–934

    Article  CAS  PubMed  Google Scholar 

  • Fleischmann RM, Tesser J, Schiff MH et al (2006) Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65(8):1006–1012

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fleischmann R, Kremer J, Cush J et al (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367(6):495–507

    Article  CAS  PubMed  Google Scholar 

  • Focosi D, Tuccori M, Maggi F (2019) Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: what do we know after 20 years of rituximab. Rev Med Virol 29(6):e2077

    Article  PubMed  Google Scholar 

  • Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P (2011) Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 106(4):644–659, quiz 660

    Article  CAS  PubMed  Google Scholar 

  • Fox RJ, Miller DH, Phillips JT et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367(12):1087–1097

    Article  CAS  PubMed  Google Scholar 

  • Galloway JB, Hyrich KL, Mercer LK et al (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50(1):124–131

    Article  CAS  Google Scholar 

  • Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA (2003) Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 42(10):1189–1196

    Article  CAS  Google Scholar 

  • Gold R, Kappos L, Arnold DL et al (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367(12):1098–1107

    Article  CAS  PubMed  Google Scholar 

  • Gopal AK, Ramchandren R, O'Connor OA et al (2012) Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 120(3):560–568

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Grim SA, Pham T, Thielke J et al (2007) Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transpl 21(5):628–632

    Article  Google Scholar 

  • Grinyo J, Charpentier B, Pestana JM et al (2010) An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 90(12):1521–1527

    Article  PubMed  Google Scholar 

  • Gross CM, Baumgartner A, Rauer S, Stich O (2012) Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod. Neurology 79(19):2006–2007

    Article  PubMed  Google Scholar 

  • Grover R, Dhir V, Aneja R et al (2006) Severe infections following leflunomide therapy for rheumatoid arthritis. Rheumatology (Oxford) 45(7):918–920

    Article  CAS  Google Scholar 

  • Gupta G, Lautenbach E, Lewis JD (2006) Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 4(12):1483–1490

    Article  PubMed  Google Scholar 

  • Hambach L, Stadler M, Dammann E, Ganser A, Hertenstein B (2002) Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation. Bone Marrow Transplant 29(11):903–906

    Article  CAS  PubMed  Google Scholar 

  • Harrington JE, Hamilton RE, Ganley-Leal L, Farraye FA, Wasan SK (2020) The immunogenicity of the influenza, pneumococcal, and hepatitis B vaccines in patients with inflammatory bowel disease treated with vedolizumab. Crohn’s Colitis 360 2(4):otaa082

    Article  Google Scholar 

  • Harris J, Hope JC, Keane J (2008) Tumor necrosis factor blockers influence macrophage responses to mycobacterium tuberculosis. J Infect Dis 198(12):1842–1850

    Article  CAS  PubMed  Google Scholar 

  • Harvey J, Tran L, Sampath R, White C, Campanile T (2019) 1410. Serious cryptococcal infections with ruxolitinib use: a case of meningitis and a review of the literature. Open Forum Infect Dis 6(Suppl 2):S513–S514

    Article  PubMed Central  Google Scholar 

  • Hauser SL, Kappos L, Arnold DL et al (2020) Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology 95(13):e1854–e1867

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hershberger RE, Starling RC, Eisen HJ et al (2005) Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 352(26):2705–2713

    Article  CAS  PubMed  Google Scholar 

  • Hillen ME, Cook SD, Samanta A, Grant E, Quinless JR, Rajasingham JK (2015) Fatal acute liver failure with hepatitis B virus infection during nataluzimab treatment in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2(2):e72

    Article  PubMed  PubMed Central  Google Scholar 

  • Hillmen P, Skotnicki AB, Robak T et al (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25(35):5616–5623

    Article  CAS  PubMed  Google Scholar 

  • Hirsch HH, Yakhontova K, Lu M, Manzetti J (2016) BK polyomavirus replication in renal tubular epithelial cells is inhibited by sirolimus, but activated by tacrolimus through a pathway involving FKBP-12. Am J Transplant 16(3):821–832

    Article  CAS  PubMed  Google Scholar 

  • Hoffman HM, Throne ML, Amar NJ et al (2008) Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58(8):2443–2452

    Article  CAS  PubMed  Google Scholar 

  • Hookey LC, Depew W, Boag A, Vanner S (2003) 6-mercaptopurine and inflammatory bowel disease: hidden ground for the cytomegalovirus. Can J Gastroenterol 17(5):319–322

    Article  CAS  PubMed  Google Scholar 

  • Hoppe-Seyler K, Sauer P, Lohrey C, Hoppe-Seyler F (2012) The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replication in vitro. Hepatology 56(1):9–16

    Article  CAS  PubMed  Google Scholar 

  • Huang H, Li X, Zhu J et al (2014) Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA 312(23):2521–2530

    Article  PubMed  CAS  Google Scholar 

  • Iannone F, Ferraccioli G, Sinigaglia L et al (2018) Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics’ register GISEA. Clin Rheumatol 37(2):315–321

    Article  CAS  PubMed  Google Scholar 

  • Ibrahim A, Ahmed M, Conway R, Carey JJ (2018) Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis. J Clin Med 8(1):15

    Article  PubMed Central  CAS  Google Scholar 

  • Issa NC, Fishman JA (2009) Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 48(6):772–786

    Article  CAS  PubMed  Google Scholar 

  • Ito H, Takazoe M, Fukuda Y et al (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 126(4):989–996; discussion 947

    Article  CAS  PubMed  Google Scholar 

  • Jain AB, Hamad I, Rakela J et al (1998) A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation 66(10):1395–1398

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jick H, Myers MW, Dean AD (1995) The risk of sulfasalazine- and mesalazine-associated blood disorders. Pharmacotherapy 15(2):176–181

    CAS  PubMed  Google Scholar 

  • Jorge S, Guerra J, Santana A, Mil-Homens C, Prata MM (2008) Mycophenolate mofetil: ten years’ experience of a renal transplant unit. Transplant Proc 40(3):700–704

    Article  CAS  PubMed  Google Scholar 

  • Judge TA, Tang A, Spain LM, Deans-Gratiot J, Sayegh MH, Turka LA (1996) The in vivo mechanism of action of CTLA4Ig. J Immunol 156(6):2294–2299

    Article  CAS  PubMed  Google Scholar 

  • Kalb RE, Fiorentino DF, Lebwohl MG et al (2015) Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol 151(9):961–969

    Article  PubMed  Google Scholar 

  • Kamar N, Milioto O, Puissant-Lubrano B et al (2010) Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 10(1):89–98

    Article  CAS  PubMed  Google Scholar 

  • Kaneko Y, Suwa A, Ikeda Y, Hirakata M (2006) Pneumocystis jiroveci pneumonia associated with low-dose methotrexate treatment for rheumatoid arthritis: report of two cases and review of the literature. Mod Rheumatol 16(1):36–38

    Article  PubMed  Google Scholar 

  • Kang HM, Kim SK, Lee JW, Chung NG, Cho B (2021) Efficacy of low dose antithymocyte globulin on overall survival, relapse rate, and infectious complications following allogeneic peripheral blood stem cell transplantation for leukemia in children. Bone Marrow Transplant 56(4):890–899

    Article  CAS  PubMed  Google Scholar 

  • Kantarjian HM, DeAngelo DJ, Stelljes M et al (2016) Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375(8):740–753

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kappos L, Radue EW, O'Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387–401

    Article  CAS  PubMed  Google Scholar 

  • Kappos L, Bar-Or A, Cree BAC et al (2018) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391(10127):1263–1273

    Article  CAS  PubMed  Google Scholar 

  • Karadkhele G, Hogan J, Magua W et al (2021) CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept. Am J Transplant 21(1):208–221

    Article  CAS  PubMed  Google Scholar 

  • Kavanaugh A, Ritchlin C, Rahman P et al (2014) Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 73(6):1000–1006

    Article  CAS  PubMed  Google Scholar 

  • Kelesidis T, Daikos G, Boumpas D, Tsiodras S (2011) Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 15(1):e2–e16

    Article  CAS  PubMed  Google Scholar 

  • KESIMPTA® (ofatumumab) [package insert] (2020) U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125326s070lbl.pdf. Accessed 15 May 2021

  • Keystone EC, Genovese MC, Klareskog L et al (2009) Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis 68(6):789–796

    Article  CAS  PubMed  Google Scholar 

  • Keystone EC, Taylor PC, Drescher E et al (2015) Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 74(2):333–340

    Article  CAS  PubMed  Google Scholar 

  • Knoll GA, Kokolo MB, Mallick R et al (2014) Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ 349:g6679

    Article  PubMed  PubMed Central  Google Scholar 

  • Komatsuda A, Okamoto Y, Hatakeyama T, Wakui H, Sawada K (2008) Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus. Clin Rheumatol 27(3):395–397

    Article  PubMed  Google Scholar 

  • Koo S, Marty FM, Baden LR (2011) Infectious complications associated with immunomodulating biologic agents. Hematol Oncol Clin North Am 25(1):117–138

    Article  PubMed  Google Scholar 

  • Kremer J, Li ZG, Hall S et al (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159(4):253–261

    Article  PubMed  Google Scholar 

  • Lee EB, Fleischmann R, Hall S et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370(25):2377–2386

    Article  PubMed  CAS  Google Scholar 

  • Leonardi CL, Kimball AB, Papp KA et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371(9625):1665–1674

    Article  CAS  PubMed  Google Scholar 

  • Lightner AL, McKenna NP, Tse CS et al (2018) Postoperative outcomes in ustekinumab-treated patients undergoing abdominal operations for Crohn’s disease. J Crohns Colitis 12(4):402–407

    Article  PubMed  Google Scholar 

  • Liu CL, Fan ST, Lo CM et al (2004) Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl 10(6):728–733

    Article  PubMed  Google Scholar 

  • Loomba R, Liang TJ (2017) Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology 152(6):1297–1309

    Article  PubMed  Google Scholar 

  • Loomba R, Rowley A, Wesley R et al (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148(7):519–528

    Article  PubMed  PubMed Central  Google Scholar 

  • Ma BB, Ostrow LW, Newsome SD (2016) Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 3(2):e203

    Article  PubMed  PubMed Central  Google Scholar 

  • Mallat SG, Tanios BY, Itani HS et al (2017) CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials. Clin J Am Soc Nephrol 12(8):1321–1336

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mantovani A, Dinarello CA, Molgora M, Garlanda C (2019) Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity 50(4):778–795

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Martin ST, Cardwell SM, Nailor MD, Gabardi S (2014) Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation. Am J Transplant 14(4):788–796

    Article  CAS  PubMed  Google Scholar 

  • Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R (2002) Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 30(12):899–903

    Article  CAS  PubMed  Google Scholar 

  • Masson P, Henderson L, Chapman JR, Craig JC, Webster AC (2014) Belatacept for kidney transplant recipients. Cochrane Database Syst Rev (11):CD010699

    Google Scholar 

  • McGuigan C, Craner M, Guadagno J et al (2016) Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 87(2):117–125

    CAS  PubMed  Google Scholar 

  • Mengel M, Marwedel M, Radermacher J et al (2003) Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrol Dial Transplant 18(6):1190–1196

    Article  CAS  PubMed  Google Scholar 

  • Merrill JT, Ginzler EM, Wallace DJ et al (2012) Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum 64(10):3364–3373

    Article  CAS  PubMed  Google Scholar 

  • Meyer DM, Jesson MI, Li X et al (2010) Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 7:41

    Article  CAS  Google Scholar 

  • Mikulska M, Lanini S, Gudiol C et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect 24(Suppl 2):S71–S82

    Article  CAS  PubMed  Google Scholar 

  • Miller DH, Khan OA, Sheremata WA et al (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348(1):15–23

    Article  CAS  PubMed  Google Scholar 

  • Molloy ES, Calabrese LH (2012) Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 64(9):3043–3051

    Article  CAS  PubMed  Google Scholar 

  • Montalban X, Hauser SL, Kappos L et al (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209–220

    Article  CAS  PubMed  Google Scholar 

  • Moreso F, Seron D, Morales JM et al (1998) Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transpl 12(3):198–205

    CAS  Google Scholar 

  • Morgan RD, O'Callaghan JM, Knight SR, Morris PJ (2012) Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Transplantation 93(12):1179–1188

    Article  CAS  PubMed  Google Scholar 

  • Morris JA, Hanson JE, Steffen BJ et al (2005) Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients. Clin Transpl 19(3):340–345

    Article  CAS  Google Scholar 

  • Moskowitz CH, Nademanee A, Masszi T et al (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385(9980):1853–1862

    Article  CAS  PubMed  Google Scholar 

  • Mulero P, Caminero AB, Neri Crespo MJ, Fernandez-Herranz R, Tellez LN (2012) Latent tuberculosis seems not to reactivate in multiple sclerosis patients on natalizumab. J Neuroimmunol 243(1–2):103–105

    Article  CAS  PubMed  Google Scholar 

  • O'Connor P, Wolinsky JS, Confavreux C et al (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365(14):1293–1303

    Article  CAS  PubMed  Google Scholar 

  • Palmer SM, Baz MA, Sanders L et al (2001) Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation 71(12):1772–1776

    Article  CAS  PubMed  Google Scholar 

  • Papp KA, Langley RG, Lebwohl M et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625):1675–1684

    Article  CAS  PubMed  Google Scholar 

  • Parikh A, Leach T, Wyant T et al (2012) Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 18(8):1470–1479

    Article  PubMed  Google Scholar 

  • Peleg AY, Husain S, Kwak EJ et al (2007) Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 44(2):204–212

    Article  CAS  PubMed  Google Scholar 

  • Perez CP, Patel N, Mardis CR, Meadows HB, Taber DJ, Pilch NA (2018) Belatacept in solid organ transplant: review of current literature across transplant types. Transplantation 102(9):1440–1452

    Article  CAS  PubMed  Google Scholar 

  • Pettit NN, Nguyen CT, Mutlu GM et al (2021) Late onset infectious complications and safety of tocilizumab in the management of COVID-19. J Med Virol 93(3):1459–1464

    Article  CAS  PubMed  Google Scholar 

  • Pham C, Kuten SA, Knight RJ, Nguyen DT, Graviss EA, Gaber AO (2020) Assessment of infectious complications in elderly kidney transplant recipients receiving induction with anti-thymocyte globulin vs basiliximab. Transpl Infect Dis 22(3):e13257

    Article  CAS  PubMed  Google Scholar 

  • Polman CH, O'Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899–910

    Article  CAS  PubMed  Google Scholar 

  • Pourfarziani V, Panahi Y, Assari S, Moghani-Lankarani M, Saadat SH (2007) Changing treatment protocol from azathioprine to mycophenolate mofetil: decrease in renal dysfunction, increase in infections. Transplant Proc 39(4):1237–1240

    Article  CAS  PubMed  Google Scholar 

  • Prajapati DN, Knox JF, Emmons J, Saeian K, Csuka ME, Binion DG (2003) Leflunomide treatment of Crohn’s disease patients intolerant to standard immunomodulator therapy. J Clin Gastroenterol 37(2):125–128

    Article  CAS  PubMed  Google Scholar 

  • Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI (1989) 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 111(8):641–649

    Article  CAS  PubMed  Google Scholar 

  • Qi WX, Huang YJ, Yao Y, Shen Z, Min DL (2013) Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis. PLoS One 8(6):e65166

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Raisch DW, Rafi JA, Chen C, Bennett CL (2016) Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA’s adverse event reporting system. Expert Opin Drug Saf 15(8):1003–1011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ratchford JN, Costello K, Reich DS, Calabresi PA (2012) Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology 79(19):2002–2004

    Article  PubMed  PubMed Central  Google Scholar 

  • Ridker PM, Everett BM, Thuren T et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119–1131

    Article  CAS  PubMed  Google Scholar 

  • Ritter ML, Pirofski L (2009) Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis 11(4):290–297

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Roberts MB, Fishman JA (2020) Immunosuppressive agents and infectious risk in transplantation: managing the “net state of immunosuppression”. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa1189

  • Rousseaux C, Lefebvre B, Dubuquoy L et al (2005) Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 201(8):1205–1215

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354(9):911–923

    Article  CAS  PubMed  Google Scholar 

  • Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB (2018) Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford) 57(6):997–1001

    Article  Google Scholar 

  • Sadovici V, Mazur-Nicorici L, Salaru V et al (2013) Do we need to screen for latent TB when initiating a methotrexate treatment? Eur Respir J 42:P2839

    Google Scholar 

  • Sakai R, Cho SK, Nanki T et al (2015) Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Res Ther 17:74

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Salliot C, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68(1):25–32

    Article  CAS  PubMed  Google Scholar 

  • Salvana EM, Salata RA (2009) Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev 22(2):274–290

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sandborn WJ, Gasink C, Gao LL et al (2012) Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 367(16):1519–1528

    Article  CAS  PubMed  Google Scholar 

  • Sandborn WJ, Feagan BG, Rutgeerts P et al (2013) Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 369(8):711–721

    Article  CAS  PubMed  Google Scholar 

  • Sandborn WJ, Su C, Sands BE et al (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376(18):1723–1736

    Article  CAS  PubMed  Google Scholar 

  • Sands BE, Sandborn WJ, Creed TJ et al (2012) Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. Gastroenterology 143(2):356–364.e351

    Article  CAS  PubMed  Google Scholar 

  • Sands BE, Sandborn WJ, Panaccione R et al (2019) Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 381(13):1201–1214

    Article  CAS  PubMed  Google Scholar 

  • Schena FP, Pascoe MD, Alberu J et al (2009) Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87(2):233–242

    Article  CAS  PubMed  Google Scholar 

  • Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF (2011) Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 13(5):R141

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H (2017) Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology 88(12):1197–1205

    Article  CAS  PubMed  Google Scholar 

  • Sethi S, Peng A, Najjar R, Vo A, Jordan SC, Huang E (2021) Infectious complications in tocilizumab-treated kidney transplant recipients. Transplantation 105(8):1818–1824

    Article  CAS  PubMed  Google Scholar 

  • Shi Y, Moriyama T, Namba Y et al (2007) Association of treatment with 15-deoxyspergualin and BK virus nephropathy in kidney allograft recipients. Clin Transpl 21(4):502–509

    Article  Google Scholar 

  • Shi Y, Wu Y, Ren Y, Jiang Y, Chen Y (2019) Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis 22(8):1361–1370

    CAS  PubMed  Google Scholar 

  • Singh N (2005) Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressive regimens. Curr Opin Infect Dis 18(4):342–345

    Article  CAS  PubMed  Google Scholar 

  • Singh JA, Cameron C, Noorbaloochi S et al (2015) Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 386(9990):258–265

    Article  PubMed  PubMed Central  Google Scholar 

  • Singh JA, Saag KG, Bridges SL Jr et al (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 68(1):1–25

    Article  Google Scholar 

  • Skoetz N, Bauer K, Elter T et al (2012) Alemtuzumab for patients with chronic lymphocytic leukaemia. Cochrane Database Syst Rev (2):CD008078

    Google Scholar 

  • Smolen J, Landewe RB, Mease P et al (2009) Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 68(6):797–804

    Article  CAS  PubMed  Google Scholar 

  • Smolen JS, Pangan AL, Emery P et al (2019) Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 393(10188):2303–2311

    Article  PubMed  Google Scholar 

  • Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER (2009) The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 330(3):864–875

    Article  CAS  PubMed  Google Scholar 

  • Strangfeld A, Listing J, Herzer P et al (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301(7):737–744

    Article  CAS  PubMed  Google Scholar 

  • Sweetser MT, Dawson KT, Bozic C (2013) Manufacturer’s response to case reports of PML. N Engl J Med 368(17):1659–1661

    Article  CAS  PubMed  Google Scholar 

  • Tanaka Y, Emoto K, Cai Z et al (2016) Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol 43(3):504–511

    Article  PubMed  Google Scholar 

  • Tang FF, Cheng YF, Xu LP et al (2020) Basiliximab as treatment for steroid-refractory acute graft-versus-host disease in pediatric patients after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 26(2):351–357

    Article  CAS  PubMed  Google Scholar 

  • Tedesco-Silva H, Felipe C, Ferreira A et al (2015) Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses. Am J Transplant 15(10):2655–2664

    Article  CAS  PubMed  Google Scholar 

  • Thiel J, Rizzi M, Engesser M et al (2017) B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther 19(1):101

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Tohyama M, Yahata Y, Yasukawa M et al (1998) Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. Arch Dermatol 134(9):1113–1117

    Article  CAS  PubMed  Google Scholar 

  • Tse E, Leung RY, Kwong YL (2015) Invasive fungal infections after obinutuzumab monotherapy for refractory chronic lymphocytic leukemia. Ann Hematol 94(1):165–167

    Article  PubMed  Google Scholar 

  • Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP (2008) Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 83(2):181–194

    Article  CAS  PubMed  Google Scholar 

  • van der Heijde D, Tanaka Y, Fleischmann R et al (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65(3):559–570

    Article  PubMed  CAS  Google Scholar 

  • van Rhee F, Casper C, Voorhees PM et al (2015) A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget 6(30):30408–30419

    Article  PubMed  PubMed Central  Google Scholar 

  • van Vollenhoven RF, Fleischmann R, Cohen S et al (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367(6):508–519

    Article  PubMed  CAS  Google Scholar 

  • Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J (2015) Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler 21(12):1600–1603

    Article  CAS  PubMed  Google Scholar 

  • Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799–807

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vogelsang GB, Arai S (2001) Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant 27(12):1255–1262

    Article  CAS  PubMed  Google Scholar 

  • von Hofsten J, Johnsson Forsberg M, Zetterberg M (2016) Cytomegalovirus retinitis in a patient who received ruxolitinib. N Engl J Med 374(3):296–297

    Article  Google Scholar 

  • von Muller L, Schliep C, Storck M et al (2006) Severe graft rejection, increased immunosuppression, and active CMV infection in renal transplantation. J Med Virol 78(3):394–399

    Article  Google Scholar 

  • Walling J (2006) From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Investig New Drugs 24(1):37–77

    Article  Google Scholar 

  • Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38(9):1261–1265

    Article  CAS  PubMed  Google Scholar 

  • Wang K, Xu X, Fan M (2018) Induction therapy of basiliximab versus antithymocyte globulin in renal allograft: a systematic review and meta-analysis. Clin Exp Nephrol 22(3):684–693

    Article  CAS  PubMed  Google Scholar 

  • Wathes R, Moule S, Milojkovic D (2013) Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 369(2):197–198

    Article  CAS  PubMed  Google Scholar 

  • Watson CJ, Bradley JA, Friend PJ et al (2005) Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. Am J Transplant 5(6):1347–1353

    Article  CAS  PubMed  Google Scholar 

  • Webster AC, Ruster LP, McGee R et al (2010) Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev (1):CD003897

    Google Scholar 

  • Winthrop KL, Baxter R, Liu L et al (2013) Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 72(1):37–42

    Article  CAS  PubMed  Google Scholar 

  • Winthrop KL, Yamanaka H, Valdez H et al (2014) Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 66(10):2675–2684

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Winthrop KL, Mariette X, Silva JT et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 24(Suppl 2):S21–S40

    Article  CAS  PubMed  Google Scholar 

  • Wysham NG, Sullivan DR, Allada G (2013) An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest 143(5):1478–1479

    Article  PubMed  PubMed Central  Google Scholar 

  • Yun H, Xie F, Delzell E et al (2016) Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheumatol 68(1):56–66

    Article  CAS  PubMed  Google Scholar 

  • Zeyda M, Poglitsch M, Geyeregger R et al (2005) Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 52(9):2730–2739

    Article  CAS  PubMed  Google Scholar 

  • Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airo P (2009) Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 36(6):1188–1194

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Disease and International Medicine, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA

    Guy Handley

  2. Department of Infectious Diseases, Ochsner Health, The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA, USA

    Jonathan Hand

Authors
  1. Guy Handley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan Hand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan Hand .

Editor information

Editors and Affiliations

  1. Heart and Vascular Institute, Pennsylvania State University, Hershey, PA, USA

    Howard J. Eisen

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Handley, G., Hand, J. (2021). Adverse Effects of Immunosuppression: Infections. In: Eisen, H.J. (eds) Pharmacology of Immunosuppression. Handbook of Experimental Pharmacology, vol 272. Springer, Cham. https://doi.org/10.1007/164_2021_550

Download citation

Publish with us

Policies and ethics

Search

Navigation